The Priority Review

Tag

Etentamig

1 story

  1. Clinical trials

    AbbVie submits BLA for etentamig to FDA for relapsed/refractory multiple myeloma

    AbbVie announced the submission of a Biologics License Application for etentamig, a second-generation BCMA x CD3 bispecific antibody, to the U.S. FDA for adults with relapsed or refractory multiple myeloma. The company cited Phase 3 CERVINO study results showing a 74.0% overall response rate versus 45.7% for investigator's choice and a 60% risk reduction in progression-free survival.